Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetics and ovarian carcinoma

H T Lynch1, M J Casey, J Lynch

  • 1Department of Preventive Medicine, Creighton University School of Medicine, Omaha, NE, USA.

Seminars in Oncology
|June 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellular stemness identifies high-risk ductal carcinoma <i>in situ</i> and offers a therapeutic interception opportunity.

bioRxiv : the preprint server for biology·2026
Same author

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.

Oncogene·2016
Same author

Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.

Oncogene·2013
Same author

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Oncogene·2013
Same author

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Gynecologic oncology·2013

Ovarian cancer, affecting 1% of women, involves genetic mutations in genes like BRCA1/BRCA2 and DNA mismatch repair genes. Early detection is crucial for survival, as many genetic factors contribute to its development.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Ovarian cancer affects 1% of American women, causing over 14,000 deaths annually.
  • Early detection is critical, with a 5-year survival rate below 20% for advanced stages.
  • The disease originates from the ovarian surface epithelium, likely involving a multi-step genetic mutation process.

Purpose of the Study:

  • To review the genetic underpinnings of ovarian cancer.
  • To highlight the role of tumor suppressor genes and proto-oncogenes.
  • To discuss the implications of genetic screening and counseling for high-risk individuals.

Main Methods:

  • Review of genetic alterations in ovarian tumors, including proto-oncogene activation and tumor suppressor gene inactivation.
  • Identification and analysis of key genes such as BRCA1, BRCA2, and DNA mismatch repair (MMR) genes.

Related Experiment Videos

  • Discussion of current screening protocols for individuals with hereditary cancer predispositions.

    • Main Results:

    • Proto-oncogenes (AKT2, Ki-RAS) and tumor suppressor genes (TP53) are implicated in ovarian cancer development.
    • Mutations in BRCA1 and BRCA2 are responsible for most hereditary ovarian cancers.
    • Increased ovarian cancer risk is observed in Lynch II syndrome (HNPCC) patients due to MMR gene mutations.

    Conclusions:

    • Genetic mutations, including those in BRCA1, BRCA2, and MMR genes, play a significant role in ovarian cancer.
    • Genetic screening and counseling are vital for managing high-risk women.
    • Further research is needed to discover more genes involved in gynecologic malignancies and understand the clinical significance of known cancer genes.